ASCO GU 2025

Combining ARPi with PARPi - discussing final OS of…

Milestones of ADT and ARPI treatment in the metastastic…

Fish-oil supplement for pts on active surveillance

Darolutamide + ADT and Doetaxel improves survivas in…

ENZA-p showed OS benefit and improvement in QoL…

Hypo-gonadism bad for survival?

OS in the TALAPRO-2 trial

Radiation vs surgery in high risk prostate cancer

Testosterone Recovery after ADT and OS

Testosterone Recovery

Radical Prostatectomy VS RT in HRPC

Durvalumab in UTUC

Who benefits most from ARPIs?

Mevrometostat - a new EZH2 inhibitor in mCRPC

MDT in OMPC

Improved Survival with Enzalutamide + Lutetium

Final OS data for TALA + Enza

Phase 2 Mevrometostat

ARPI for which patients?

Final OS analyses

Mevrometostat + Enza: New option for mCRPC

Darolutamide + ADT reduces risk of progression or death…

UTUC de Neoadj. Durvalumab+Kemo

Yuksek risk PCa da RP vs RT

Testosteron Geri Gelisi ve Sagkalim

Hangi hastalarda ADT+ARPI

Enza+Lu ile artmis sagkalim

New data but no new conclusion

Exciting new substances - but don't over-estimate phase…

KIM-1 - The most interesting biomarker for RCC?

AVION trial at mRCC

Proactive coaching of patients with TKI +/- IO therapy

New agents / new mode of actions

KIM-1 in CheckMate 214

Firstline Update Kidney Cancer

Prognostic and predictive biomarkers in mRCC: Looking…

New data nccRCC

KIM-1 in mRCC

Casdatifan in refracting RCC

Cáncer de células renales avanzado: añadir más fármacos…

Neoadjuvant chemo-immunotherapy in UTUC: new evidence…

Exploratory analyses of pCR in NIAGARA: who benefits…

New data, but no new insights for adjuvant treatment of…

ADC + ICI - The future for MIBC?

New drugs in mUC: The active field of ADCs

Durvalumab + Platinum-based chemotherapy shows…

Bladder-sparing approaches - are we there yet?

Neoadjuvant treatment for UTUC

Updates neo/adjuvant therapy in MIBC

Nivo adjuvant in MIBC - a new standard

Phase 2 Mevrometastat

Adjuvant Nivo - independent from previous therapy

Sacituzumab Tirumotecan shows promising antitumor…

Preliminary results of neoadjuvant chemoimmunotherapy…

Promising combination for perioperative setting

HER2 - new marker for bladder preservation

The role of ctDNA in bladder cancer

A possible new standard for mUC

ASCO GU 25 - Summary: Urothelial Cancer

New FGFR3 inhibitor

Promising combination for perioperative setting

Nuevos fármacos en mUC: El campo activo de las ADCs

RPLND in metastatic Seminoma

Cáncer de testículo: reinventar la rueda